Yes, Furmonertinib is a targeted therapy drug, classified as a third-generation EGFR-TKI. It can specifically inhibit EGFR gene mutations (such as T79···【Read More】
Update: 2026-01-30Source: Haiou HealthViews: 75
The price of Furmonertinib is affected by factors such as drug specifications, regional disparities, and medical insurance policies, with the cost per···【Read More】
Update: 2026-01-30Source: Haiou HealthViews: 81
The recommended oral dose of Furmonertinib is 80 mg once daily, and it can be taken either on an empty stomach or with food.【Read More】
Update: 2026-01-30Source: Haiou HealthViews: 75
Furmonertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily indicated for the treatment of ···【Read More】
Update: 2026-01-30Source: Haiou HealthViews: 84
Furmonertinib is primarily indicated for patients with non-small cell lung cancer (NSCLC) harboring specific mutations in the epidermal growth factor ···【Read More】
Update: 2026-01-30Source: Haiou HealthViews: 79
On January 6, 2025, Nuvalent, Inc. announced that its independently developed taletrectinib has been approved by the National Medical Products Adminis···【Read More】
Update: 2026-01-30Source: Haiou HealthViews: 82
On December 20, 2024, the National Medical Products Administration (NMPA) granted conditional approval for the marketing of Talrectinib Adipate Capsul···【Read More】
Update: 2026-01-30Source: Haiou HealthViews: 82
Taletrectinib should be stored protected from light at a temperature below 30°C, kept in its original packaging to prevent moisture absorption.【Read More】
Update: 2026-01-30Source: Haiou HealthViews: 84
Taletrectinib can be taken either on an empty stomach or after meals, but it must be administered at a fixed time each day to maintain stable blood dr···【Read More】
Update: 2026-01-30Source: Haiou HealthViews: 79
The recommended adult dosage of Taletrectinib is generally one oral dose once daily. The specific dosage shall be adjusted based on the patient's ···【Read More】
Update: 2026-01-30Source: Haiou HealthViews: 74
Taletrectinib is a targeted therapeutic agent indicated for the treatment of non-small cell lung cancer (NSCLC) positive for ALK/ROS1 gene fusions. It···【Read More】
Update: 2026-01-30Source: Haiou HealthViews: 90
The retail price of taletrectinib is affected by factors such as region, medical insurance policies and purchasing channels, generally ranging from 72···【Read More】
Update: 2026-01-29Source: Haiou HealthViews: 80
Tarlatamab is a targeted therapeutic agent indicated for the treatment of small cell lung cancer (SCLC). As it has not yet been approved for the domes···【Read More】
Update: 2026-01-29Source: Haiou HealthViews: 82
Taletrectinib has not yet been included in the national medical insurance catalog, and patients need to purchase it at their own expense. This medicat···【Read More】
Update: 2026-01-29Source: Haiou HealthViews: 77
The price of taletrectinib varies depending on factors such as region, dosage specification, and medical insurance policies. It generally ranges from ···【Read More】
Update: 2026-01-29Source: Haiou HealthViews: 75
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH



